Xinwei Zhang

Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

CCL5 Orchestrates Paradoxical Immune Landscapes in NSCLC: Simultaneous Recruitment of Effector and Suppressor Cells Shapes Immunotherapy Resistance.

CCL5 Orchestrates Paradoxical Immune Landscapes in NSCLC: Simultaneous Recruitment of Effector and Suppressor Cells Shapes Immunotherapy Resistance.

Journal: Cancers
Published: March 02, 2026

DEW-Net: A W-Shaped Dual-Encoder Network With Attention Fusion Mechanisms for Pathological H&E Image Segmentation.

DEW-Net: A W-Shaped Dual-Encoder Network With Attention Fusion Mechanisms for Pathological H&E Image Segmentation.

Journal: IEEE journal of biomedical and health informatics
Published: January 27, 2026

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)
Published: October 09, 2025

Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.

Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.

Journal: Scientific reports
Published: October 06, 2025

A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer.

A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer.

Journal: Cancer immunology, immunotherapy : CII
Published: August 07, 2025

Research Progress on Pathogenesis and Treatment of NUT Carcinoma

Research Progress on Pathogenesis and Treatment of NUT Carcinoma

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: July 19, 2024

Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of 
Non-small Cell Lung Cancer with MET Alterations

Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of 
Non-small Cell Lung Cancer with MET Alterations

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: November 20, 2023

Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy: a case report.

Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy: a case report.

Journal: Gland surgery
Published: July 13, 2022

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer
Published: April 03, 2022

The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma.

The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma.

Journal: Cancer biology & medicine
Published: August 30, 2021

Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma.

Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma.

Journal: Cancer biology & medicine
Published: August 17, 2021

Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.

Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.

Journal: Cancer biology & medicine
Published: August 11, 2021
Showing 1-12 of 40

Last Updated: 09/26/2026